NCT00133900View on ClinicalTrials.gov

Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy

UnknownOBSERVATIONAL
Enrollment

276

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Hormone Refractory Prostate CancerProstate Cancer
Interventions
PROCEDURE

Phlebotomy

Peripheral blood draws for evaluation of circulating tumor cells

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

Sponsors

Lead Sponsor

Immunicon
All Listed Sponsors
lead

Immunicon

INDUSTRY

NCT00133900 - Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy | Biotech Hunter | Biotech Hunter